Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related SPPI
8-K Filings Shows Spectrum Pharma Signs Partnersship With Servier Canada, Will Receive $6M Upfront
Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
Related GALT
Morning Market Losers
Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

Analysts at HC Wainwright initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) with a “buy” rating. The target price for Spectrum Pharmaceuticals is set to $15. Spectrum's shares closed at $8.49 on Friday.

Ascendiant Capital initiated coverage on shares of Galectin Therapeutics (NASDAQ: GALT) with a “buy” rating. The target price for Galectin Therapeutics is set to $13. Galectin Therapeutics' shares closed at $11.00 on Friday.

Analysts at Morgan Stanley initiated coverage on shares ITC Holdings (NYSE: ITC) with an “overweight” rating. The target price for ITC Holdings is set to $105. ITC's stock closed at $93.13 on Friday.

Atlantic Equities initiated coverage on shares of Facebook (NASDAQ: FB) with an “overweight” rating. The target price for Facebook is set to $63. Facebook's shares closed at $51.04 on Friday.

Latest Ratings for SPPI

DateFirmActionFromTo
Apr 2015FBR CapitalInitiates Coverage onOutperform
Mar 2015JefferiesMaintainsHold
Feb 2015Roth CapitalDowngradesBuy

View More Analyst Ratings for SPPI
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (FB + GALT)

Get Benzinga's Newsletters